Why Eli Lilly is a top GLP-1 stock: Roundhill CEO

Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more productПодробнее

Why Eli Lilly is a top pick to capitalize on GLP-1 drug crazeПодробнее

Excitement grows around Eli Lilly's GLP-1 drugs in Q2 earningsПодробнее

FDA vs. Eli Lilly: Will Compounding Tirzepatide / GLP-1 Be Stopped?Подробнее

Eli Lilly CEO talks expanding innovation past obesity drugsПодробнее

What Eli Lilly, Novo Nordisk earnings show about GLP-1 salesПодробнее

Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound resultПодробнее

Eli Lilly CEO David Ricks on GLP-1 and obesity drugsПодробнее

Eli Lilly CEO on why food companies haven't seen a big impact on salesПодробнее

Inside Eli Lilly's Pipeline New GLP 1sПодробнее

Eli Lilly CEO on compounded versions of weight loss drugsПодробнее

Chart of the Day: Eli LillyПодробнее

Market Navigator: Playing Big Pharma and Eli LillyПодробнее

Eli Lilly CEO on Fighting Obesity, Developing New DrugsПодробнее

Eli Lilly is a 'great destination for investors', says Deutsche Bank's James Shin after upgradeПодробнее

Novo Nordisk, Eli Lilly have strong first-mover advantage: analystПодробнее

Eli Lilly: Becoming the world's biggest pharmaceutical company 1876-2024Подробнее

Eli Lilly CEO David Ricks on Q2 results: Seeing unbelievable demand for Zepbound and MounjaroПодробнее